Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.51 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.45 |
| ▸ | CDC25B | P30305 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | PDE4A | P27815 | 1/20 | 0.45 |
| ▸ | SNCA | P37840 | 1/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7083555 | 1.00 | PTPN1 (0.51) | PTPN1PSEN1TRPV1PTPN2CDC25B | |
| SCHEMBL8417694 | 0.84 | PTPN1 (0.49) | PTPN1PSEN1TRPV1PTPN2CDC25B | |
| SCHEMBL16435131 | 0.78 | PTPN1 (0.56) | PTPN1PSEN1TRPV1PTPN2CDC25B | |
| SCHEMBL7082821 | 0.78 | PTGS1 (0.54) | PTPN1PSEN1TRPV1PTPN2CDC25B | |
| SCHEMBL7050031 | 0.78 | PTGS1 (0.54) | PTPN1PSEN1TRPV1PTPN2CDC25B | |
| SCHEMBL5561790 | 0.77 | PTPN1 (0.56) | PTPN1PSEN1TRPV1PTPN2CDC25B | |
| SCHEMBL5563077 | 0.77 | PTPN1 (0.56) | PTPN1PSEN1TRPV1PTPN2CDC25B | |
| SCHEMBL28511946 | 0.77 | PTPN1 (0.49) | PTPN1PSEN1TRPV1PTPN2CDC25B | |
| SCHEMBL14273810 | 0.76 | PTPN1 (0.57) | PTPN1PSEN1TRPV1PTPN2CDC25B | |
| SCHEMBL4762469 | 0.76 | PTPN1 (0.57) | PTPN1PSEN1TRPV1PTPN2CDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030182679-A1 | Reducing homogentisate degradation by reducing the activity of homogentisate 1,2-dioxygenase (HGD), maleyl-acetoacetate isomerase(MAAI) and/or fumaryl acetoacetate hydrolase(FAAH) activity | SUNGENE GMBH & CO. KGAA (DE) | 2003-09-25 | — | — | US | disclosed |
| WO-2001012827-A9 | METHOD FOR PRODUCTION OF TRANSGENIC PLANTS WITH INCREASED TOCOPHEROL CONTENT | SUNGENE GMBH & CO KGAA (DE) | 2002-05-10 | — | — | WO | disclosed |
| EP-1200598-A2 | METHOD FOR PRODUCTION OF TRANSGENIC PLANTS WITH INCREASED TOCOPHEROL CONTENT | Sungene GmbH & Co. KGaA (DE) | 2002-05-02 | — | — | EP | disclosed |
| WO-2001012827-A2 | METHOD FOR PRODUCTION OF TRANSGENIC PLANTS WITH INCREASED TOCOPHEROL CONTENT | SUNGENE GMBH & CO. KGAA (DE) | 2001-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030182679-A1 | Reducing homogentisate degradation by reducing the activity of homogentisate 1,2-dioxygenase (HGD), maleyl-acetoacetate isomerase(MAAI) and/or fumaryl acetoacetate hydrolase(FAAH) activity | FAH, GCDH, FH | PTPN1 4801/4885PSEN1 4458/4885TRPV1 3531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.